|
1
|
Porter KE and Turner NA: Cardiac
fibroblasts: At the heart of myocardial remodeling. Pharmacol Ther.
123:255–278. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Fan D, Takawale A, Lee J and Kassiri Z:
Cardiac fibroblasts, fibrosis and extracellular matrix remodeling
in heart disease. Fibrogenesis Tissue Repair. 5(15)2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Leask A: Getting to the heart of the
matter: New insights into cardiac fibrosis. Circ Res.
116:1269–1276. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Leask A: TGFbeta, cardiac fibroblasts, and
the fibrotic response. Cardiovasc Res. 74:207–212. 2007.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Takeda N, Manabe I, Uchino Y, Eguchi K,
Matsumoto S, Nishimura S, Shindo T, Sano M, Otsu K, Snider P, et
al: Cardiac fibroblasts are essential for the adaptive response of
the murine heart to pressure overload. J Clin Invest. 120:254–265.
2010.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Weber KT, Sun Y, Bhattacharya SK, Ahokas
RA and Gerling IC: Myofibroblast-mediated mechanisms of
pathological remodelling of the heart. Nat Rev Cardiol. 10:15–26.
2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Thannickal VJ, Zhou Y, Gaggar A and Duncan
SR: Fibrosis: Ultimate and proximate causes. J Clin Invest.
124:4673–4677. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Trujillo RD, Yue SB, Tang Y, O'Gorman WE
and Chen CZ: The potential functions of primary microRNAs in target
recognition and repression. EMBO J. 29:3272–3285. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
11
|
Lima J Jr, Batty JA, Sinclair H and
Kunadian V: MicroRNAs in ischemic heart disease: From
pathophysiology to potential clinical applications. Cardiol Rev.
25:117–125. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Quiat D and Olson EN: MicroRNAs in
cardiovascular disease: From pathogenesis to prevention and
treatment. J Clin Invest. 123:11–18. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Thum T and Lorenzen JM: Cardiac fibrosis
revisited by microRNA therapeutics. Circulation. 126:800–802.
2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Schellings MW, Vanhoutte D, van Almen GC,
Swinnen M, Leenders JJ, Kubben N, van Leeuwen RE, Hofstra L,
Heymans S and Pinto YM: Syndecan-1 amplifies angiotensin II-induced
cardiac fibrosis. Hypertension. 55:249–256. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhang Y, Huang XR, Wei LH, Chung AC, Yu CM
and Lan HY: miR-29b as a therapeutic agent for angiotensin
II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling. Mol
Ther. 22:974–985. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Schneider MD: Serial killer: Angiotensin
drives cardiac hypertrophy via TGF-beta1. J Clin Invest.
109:715–716. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Iwata M, Cowling RT, Yeo SJ and Greenberg
B: Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to
treat cardiac remodeling and heart failure. J Mol Cell Cardiol.
51:542–547. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Iwaya T, Yokobori T, Nishida N, Kogo R,
Sudo T, Tanaka F, Shibata K, Sawada G, Takahashi Y, Ishibashi M, et
al: Downregulation of miR-144 is associated with colorectal cancer
progression via activation of mTOR signaling pathway.
Carcinogenesis. 33:2391–2397. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Guo Y, Ying L, Tian Y, Yang P, Zhu Y, Wang
Z, Qiu F and Lin J: miR-144 downregulation increases bladder cancer
cell proliferation by targeting EZH2 and regulating Wnt signaling.
FEBS J. 280:4531–4538. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zha W, Cao L, Shen Y and Huang M: Roles of
Mir-144-ZFX pathway in growth regulation of non-small-cell lung
cancer. PLoS One. 8(e74175)2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhao M, Huang J, Gui K, Xiong M, Cai G, Xu
J, Wang K, Liu D, Zhang X and Yin W: The downregulation of miR-144
is associated with the growth and invasion of osteosarcoma cells
through the regulation of TAGLN expression. Int J Mol Med.
34:1565–1572. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cui SQ and Wang H: MicroRNA-144 inhibits
the proliferation, apoptosis, invasion, and migration of
osteosarcoma cell line F5M2. Tumour Biol. 36:6949–6958.
2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Bao H, Li X, Li H, Xing H, Xu B, Zhang X
and Liu Z: MicroRNA-144 inhibits hepatocellular carcinoma cell
proliferation, invasion and migration by targeting ZFX. J Biosci.
42:103–111. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gu J, Liu X, Li J and He Y: MicroRNA-144
inhibits cell proliferation, migration and invasion in human
hepatocellular carcinoma by targeting CCNB1. Cancer Cell Int.
19(15)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Siddiqui MR, Akhtar S, Shahid M, Tauseef
M, McDonough K and Shanley TP: miR-144 mediated inhibition of ROCK1
protects against LPS induced lung endothelial hyperpermeability. Am
J Respir Cell Mol Biol. 61:257–265. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
He Q, Wang F, Honda T, James J, Li J and
Redington A: Loss of miR-144 signaling interrupts extracellular
matrix remodeling after myocardial infarction leading to worsened
cardiac function. Sci Rep. 8(16886)2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Li J, Cai SX, He Q, Zhang H, Friedberg D,
Wang F and Redington AN: Intravenous miR-144 reduces left
ventricular remodeling after myocardial infarction. Basic Res
Cardiol. 113(36)2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Jiang DS, Bian ZY, Zhang Y, Zhang SM, Liu
Y, Zhang R, Chen Y, Yang Q, Zhang XD, Fan GC and Li H: Role of
interferon regulatory factor 4 in the regulation of pathological
cardiac hypertrophy. Hypertension. 61:1193–1202. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Jiang DS, Wei X, Zhang XF, Liu Y, Zhang Y,
Chen K, Gao L, Zhou H, Zhu XH, Liu PP, et al: IRF8 suppresses
pathological cardiac remodelling by inhibiting calcineurin
signalling. Nat Commun. 5(3303)2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Brown RD, Ambler SK, Mitchell MD and Long
CS: The cardiac fibroblast: Therapeutic target in myocardial
remodeling and failure. Annu Rev Pharmacol Toxicol. 45:657–687.
2005.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wei C, Kim IK, Kumar S, Jayasinghe S, Hong
N, Castoldi G, Catalucci D, Jones WK and Gupta S: NF-κB mediated
miR-26a regulation in cardiac fibrosis. J Cell Physiol.
228:1433–1442. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Matkovich SJ, Wang W, Tu Y, Eschenbacher
WH, Dorn LE, Condorelli G, Diwan A, Nerbonne JM and Dorn GW II:
MicroRNA-133a protects against myocardial fibrosis and modulates
electrical repolarization without affecting hypertrophy in
pressure-overloaded adult hearts. Circ Res. 106:166–175.
2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wang X, Wang HX, Li YL, Zhang CC, Zhou CY,
Wang L, Xia YL, Du J and Li HH: MicroRNA Let-7i negatively
regulates cardiac inflammation and fibrosis. Hypertension.
66:776–785. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yuan J, Chen H, Ge D, Xu Y, Xu H, Yang Y,
Gu M, Zhou Y, Zhu J, Ge T, et al: Mir-21 promotes cardiac fibrosis
after myocardial infarction via targeting Smad7. Cell Physiol
Biochem. 42:2207–2219. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wei Y, Yan X, Yan L, Hu F, Ma W, Wang Y,
Lu S, Zeng Q and Wang Z: Inhibition of microRNA155 ameliorates
cardiac fibrosis in the process of angiotensin II induced cardiac
remodeling. Mol Med Rep. 16:7287–7296. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Deng P, Chen L, Liu Z, Ye P, Wang S, Wu J,
Yao Y, Sun Y, Huang X, Ren L, et al: MicroRNA-150 inhibits the
activation of cardiac fibroblasts by regulating c-Myb. Cell Physiol
Biochem. 38:2103–2122. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
E L, Jiang H and Lu Z: MicroRNA-144
attenuates cardiac ischemia/reperfusion injury by targeting FOXO1.
Exp Ther Med. 17:2152–2160. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Xie T, Liang J, Guo R, Liu N, Noble PW and
Jiang D: Comprehensive microRNA analysis in bleomycin-induced
pulmonary fibrosis identifies multiple sites of molecular
regulation. Physiol Genomics. 43:479–487. 2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Liu Z, Yi J, Ye R, Liu J, Duan Q, Xiao J
and Liu F: miR-144 regulates transforming growth factor-β1 iduced
hepatic stellate cell activation in human fibrotic liver. Int J
Clin Exp Pathol. 8:3994–4000. 2015.PubMed/NCBI
|
|
40
|
Bahudhanapati H, Tan J, Dutta JA, Strock
SB, Sembrat J, Alvarez D, Rojas M, Jäger B, Prasse A, Zhang Y and
Kass DJ: MicroRNA-144-3p targets relaxin/insulin-like family
peptide receptor 1 (RXFP1) expression in lung fibroblasts from
patients with idiopathic pulmonary fibrosis. J Biol Chem.
294:5008–5022. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Chan EC, Dusting GJ, Guo N, Peshavariya
HM, Taylor CJ, Dilley R, Narumiya S and Jiang F: Prostacyclin
receptor suppresses cardiac fibrosis: Role of CREB phosphorylation.
J Mol Cell Cardiol. 49:176–185. 2010.PubMed/NCBI View Article : Google Scholar
|
|
42
|
El Jamali A, Freund C, Rechner C,
Scheidereit C, Dietz R and Bergmann MW: Reoxygenation after severe
hypoxia induces cardiomyocyte hypertrophy in vitro: Activation of
CREB downstream of GSK3beta. FASEB J. 18:1096–1098. 2004.PubMed/NCBI View Article : Google Scholar
|
